Pharmacovigilance – News and Features

Nanogen acquires rights to genetic markers related to schizophrenia and responses to antipsychotic therapies from Diagnostics CRC and Queensland University of Technology

Study suggests adult stem cells cultivated from patients' own blood can improve the patients’ life whose lower extremities are affected by peripheral vascular disease.

Researchers derive mesenchymal stem cells from human fat tissue and engineered them into suicide genes that destroy tumors.

The Safety Intelligence Program applies technology and methodology to deliver an Intelligence System that will be used to support drug safety risk assessment at early stages of the drug discovery process.

PrimeCell has provided pre-clinical studies for a clinical trial to assess the efficacy of implanting autologous bone marrow stem cells into spinal cord injury patients.

University of Alberta researchers have miniaturized and automated a diagnostic test for cancer onto a microfluidic chip.

VASTox will use its zebrafish technology platform to blind-screen selections of known compounds for safety and toxicity to validate to its clients how this technology can predict unwanted side effects.

Zora will provide laboratory services to pharmaceutical industry in the area of metabolomics and associated bioinformatics.

Inovio’s Phase I/II study of patients with recurrent breast cancer showed safety, tolerability and achieved a 75% complete tumor response rate.

The genes discovered are important potential targets for drugs that could selectively cut off a tumor's blood supply without affecting the blood vessels.